Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) will be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The firm had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. During the same period in the previous year, the company earned ($0.15) EPS. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock traded down $0.08 during mid-day trading on Tuesday, reaching $8.47. 237,769 shares of the stock traded hands, compared to its average volume of 535,584. The stock’s fifty day simple moving average is $7.77 and its two-hundred day simple moving average is $6.24. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.95. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Analyst Ratings Changes

Several equities research analysts recently commented on ZVRA shares. Roth Mkm lifted their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, September 18th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. JMP Securities started coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. Finally, Guggenheim assumed coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 price objective for the company. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Zevra Therapeutics has a consensus rating of “Buy” and a consensus price target of $20.83.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.